These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 38326735)
1. A promising target for breast cancer: B7-H3. Jiang Y; Liu J; Chen L; Qian Z; Zhang Y BMC Cancer; 2024 Feb; 24(1):182. PubMed ID: 38326735 [TBL] [Abstract][Full Text] [Related]
2. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3. Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149 [TBL] [Abstract][Full Text] [Related]
3. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention. Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439 [TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349 [TBL] [Abstract][Full Text] [Related]
5. B7-H3/CD276: An Emerging Cancer Immunotherapy. Zhou WT; Jin WL Front Immunol; 2021; 12():701006. PubMed ID: 34349762 [TBL] [Abstract][Full Text] [Related]
6. B7-H3 in Brain Malignancies: Immunology and Immunotherapy. Guo X; Chang M; Wang Y; Xing B; Ma W Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196 [TBL] [Abstract][Full Text] [Related]
7. The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages. Park R; Yu J; Shahzad M; Lee S; Ji JD Immunol Res; 2024 Aug; 72(4):526-537. PubMed ID: 38265550 [TBL] [Abstract][Full Text] [Related]
8. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma. Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953 [TBL] [Abstract][Full Text] [Related]
9. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients. Pizon M; Schott DS; Pachmann U; Pachmann K Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585 [TBL] [Abstract][Full Text] [Related]
10. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Yang S; Wei W; Zhao Q Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947 [TBL] [Abstract][Full Text] [Related]
12. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. Maeda N; Yoshimura K; Yamamoto S; Kuramasu A; Inoue M; Suzuki N; Watanabe Y; Maeda Y; Kamei R; Tsunedomi R; Shindo Y; Inui M; Tamada K; Yoshino S; Hazama S; Oka M Ann Surg Oncol; 2014 Dec; 21 Suppl 4(Suppl 4):S546-54. PubMed ID: 24562936 [TBL] [Abstract][Full Text] [Related]
13. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells. Shao L; Yu Q; Xia R; Zhang J; Gu S; Yu D; Zhuang Z Pathol Res Pract; 2021 Aug; 224():153461. PubMed ID: 34265738 [TBL] [Abstract][Full Text] [Related]
14. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240 [TBL] [Abstract][Full Text] [Related]
15. The role of B7-H3 in tumors and its potential in clinical application. Feng R; Chen Y; Liu Y; Zhou Q; Zhang W Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689 [TBL] [Abstract][Full Text] [Related]
16. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy. Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969 [TBL] [Abstract][Full Text] [Related]
17. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma. Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ Front Immunol; 2021; 12():757047. PubMed ID: 34675936 [TBL] [Abstract][Full Text] [Related]
18. Targeting CD276 for T cell-based immunotherapy of breast cancer. Hagelstein I; Wessling L; Rochwarger A; Zekri L; Klimovich B; Tegeler CM; Jung G; Schürch CM; Salih HR; Lutz MS J Transl Med; 2024 Oct; 22(1):902. PubMed ID: 39367484 [TBL] [Abstract][Full Text] [Related]
19. Gastric Carcinomas with Stromal B7-H3 Expression Have Lower Intratumoural CD8+ T Cell Density. Ulase D; Behrens HM; Krüger S; Zeissig S; Röcken C Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669921 [TBL] [Abstract][Full Text] [Related]
20. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. Liu C; Zhang G; Xiang K; Kim Y; Lavoie RR; Lucien F; Wen T Cancer Immunol Immunother; 2022 Jul; 71(7):1549-1567. PubMed ID: 34739560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]